文献速递肾移植

研究设计:人类白细胞抗原I类分子A*02嵌合抗原受体调节性T细胞在肾移植中的应用

Study Design: Human Leukocyte Antigen Class I Molecule A∗02-Chimeric Antigen Receptor Regulatory T Cells in Renal Transplantation.
PubMed 文献 · Kidney Int Rep · 2022-04-06

本文介绍STEADFAST研究设计,一项首次人体、I/IIa期、多中心、开放标签、单次递增剂量、剂量探索研究,评估TX200-TR101在活体肾移植受者中的安全性和其他终点。最多15例受者接受TX200-TR101并随访84周,另设最多6例对照队列。主要终点为输注后28天内治疗中出现不良事件的发生率和严重程度。

要点

  • TX200-TR101为自体HLA-A*02-CAR调节性T细胞疗法,用于HLA-A*02错配肾移植。
  • STEADFAST研究为首次人体I/IIa期多中心开放标签单次递增剂量剂量探索研究。
  • 主要终点为TX200-TR101输注后28天内治疗中出现不良事件的发生率和严重程度。

核心结论

  • TX200-TR101在HLA-A*02错配肾移植后具有预防免疫介导的移植物排斥和诱导免疫耐受的潜力。

研究设计与样本

  • STEADFAST研究为首次人体、I/IIa期、多中心、开放标签、单次递增剂量、剂量探索研究。
  • 最多15例活体肾移植受者将接受TX200-TR101,并移植后随访共84周。
  • 另设最多6例移植受者对照队列。

主要发现

  • 主要终点为TX200-TR101输注后28天内治疗中出现不良事件的发生率和严重程度。
  • 其他终点包括额外安全性参数、临床和肾脏结局参数以及生物标志物评估。

临床怎么用

  • 所有移植受者将接受标准免疫抑制方案,TX200-TR101队列意图强化减量。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Cell therapy with regulatory T cells (Tregs) in solid organ transplantation is a promising approach for the prevention of graft rejection and induction of immunologic tolerance. Previous clinical studies have demonstrated the safety of Tregs in renal transplant recipients. Antigen-specific Tregs, such as chimeric antigen receptor (CAR)-Tregs, are expected to be more efficacious than polyclonal Tregs in homing to the target antigen. We have developed an autologous cell therapy (TX200-TR101) where a human leukocyte antigen (HLA) class I molecule A∗02 (HLA-A∗02)-CAR is introduced into autologous naive Tregs from a patient with HLA-A∗02-negative end-stage renal disease (ESRD) awaiting an HLA-A∗02-positive donor kidney. METHODS: This article describes the design of the STEADFAST study, a first-in-human, phase I/IIa, multicenter, open-label, single-ascending dose, dose-ranging study to assess TX200-TR101 in living-donor renal transplant recipients. Up to 15 transplant recipients will receive TX200-TR101 and will be followed up for a total of 84 weeks post-transplant, alongside a control cohort of up to 6 transplant recipients. All transplant recipients will receive a standard of care immunosuppressive regimen, with the intent of intensified tapering of the regimen in the TX200-TR101 cohort. RESULTS: The primary end point is the incidence and severity of treatment-emergent adverse events (AEs) within 28 days post-TX200-TR101 infusion. Other end points include additional safety parameters, clinical and renal outcome parameters, and the evaluation of biomarkers. CONCLUSION: The STEADFAST study represents the next frontier in adoptive cell therapies. TX200-TR101 holds great potential to prevent immune-mediated graft rejection and induce immunologic tolerance after HLA-A∗02-mismatched renal transplantation.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Schreeb K, Culme-Seymour E, Ridha E, et al. Study Design: Human Leukocyte Antigen Class I Molecule A∗02-Chimeric Antigen Receptor Regulatory T Cells in Renal Transplantation. Kidney Int Rep. 2022. PMID: 35694562. doi:10.1016/j.ekir.2022.03.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。